Loading clinical trials...

Treating Alzheimer's and Dementia With D-ribose | Clinical Trials | Clareo Health

TERMINATEDNA

Treating Alzheimer's and Dementia With D-ribose

NCT02260141•Practitioners Alliance Network

View on ClinicalTrials.gov

Summary

To study the effectiveness of d-ribose in treating Alzheimer's and Dementia

Detailed Description

Clinical experience and the pathophysiology of Alzheimer's, including neuronal insulin resistance, suggests that ribose improves clinical outcomes. This study will add ribose 5 gm 3 X day for 8 weeks to monitor outcomes in a pilot study.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.
•Must have a caregiver living with them.

Exclusion Criteria

•Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.
•Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.

Locations (1)

PAN

Kailua, Hawaii, United States

Key Dates

Start Date

September 1, 2014

Primary Completion Date

October 1, 2017

Completion Date

October 1, 2017

Last Updated

May 8, 2020

Enrollment

ACTUAL participants

Conditions

AlzheimersDementia

Interventions

d-ribose

DIETARY_SUPPLEMENT

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150

Alzheimers Disease

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treating Alzheimer's and Dementia With D-ribose

Inclusion Criteria

Exclusion Criteria

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Testing the Pain Clinical Practice Guideline